Several groups have recently validated that KRAS mutations are a negative predictor of colorectal carcinoma response to monoclonal antibodies (e.g. panitumimab and cextuximab) targeting epidermal growth factor receptor (EGFR) [22], [23]. The gene discussed is EGFR; the disease is colorectal carcinoma.